Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-22
2009-06-23
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S093000
Reexamination Certificate
active
07550478
ABSTRACT:
The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
REFERENCES:
patent: 3366635 (1968-01-01), Villani et al.
patent: 4948796 (1990-08-01), Hiraiwa et al.
patent: 5726325 (1998-03-01), Yoshida et al.
patent: 6365588 (2002-04-01), Bishop et al.
patent: 2003/0114432 (2003-06-01), Clare et al.
patent: WO 88/03138 (1988-05-01), None
patent: WO 92/00293 (1992-01-01), None
patent: WO 98/11096 (1998-03-01), None
patent: WO 98/11097 (1998-03-01), None
patent: 03084931 (2003-10-01), None
patent: WO 03/084931 (2003-10-01), None
patent: WO 2004/043966 (2004-05-01), None
patent: WO 2004/058742 (2004-07-01), None
patent: WO 2007/002254 (2007-01-01), None
patent: WO 2007/050380 (2007-05-01), None
patent: WO 2007/050383 (2007-05-01), None
patent: WO 2007/050401 (2007-05-01), None
patent: WO 2008/008310 (2008-01-01), None
Dermer (Bio/Technology, 1994, 12:320).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, pp. 1-6.
P. Ma, et al. Cancer Res., vol. 65 (4), pp. 1479-1488 (2005).
P. Ma. et al. Cancer Res., vol. 63, pp. 6272-6281 (2003).
J. Christensen, et al., Cancer Res., vol. 63, pp. 7345-7355 (2003).
M. Sattler, et al., Cancer Res., vol. 63, pp. 5462-5469 (2003).
Puri, N et al., Cancer Research, vol. 67, No. 8, pp. 3529-3534 (2007), “A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts”.
Zou, HY et al., Cancer Research, vol. 67, No. 9, pp. 4408-4417 (2007), “An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms”.
Cassinelli, G et al., Molecular Cancer Therapeutics, vol. 5, No. 9, pp. 2388-2397 (2006), “Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1”.
Martens, T et al., Clinical Cancer Research, vol. 12, No. 20, 6144-6152 (2006), “A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo”.
Christensen, JG et al., Cancer Research, vol. 63, pp. 7345-7355 (2003), “A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo”.
Ross, R et al., Poster B249, 2007 AARC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 2007, “A Phase 2 Study of the Dual MET/VEGFR2 Inhibitor XL880 in Patients (pts) with Papillary Renal Carcinoma (PRC)”.
Christensen, J. et al., Cancer Letters, vol. 225, pp. 1-26 (2005), “c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention”.
Dinsmore Christopher J.
Gabarda Ortega Ana Esther
Guerin David J.
Jewell James P.
Katz Jason D.
Merck & Co. , Inc.
Muthard David A.
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090182